Trevena, Inc. (TRVN )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol TRVN
- Company Trevena, Inc.
- Price $0.01
- Changes Percentage 2700
- Change 0.0108
- Day Low $0.01
- Day High $0.01
- Year High $1.93
- Year Low $0
- Market Cap $864
- Price Avg 50 EMA (D) $0.01
- Price Avg 200 EMA (D) $0.42
- Exchange OTC
- Volume 109
- Average Volume 734
- Open $0.01
- Previous Close $0
- EPS -48.89
- PE 0.00
- Earnings Announcement 2026-02-25 12:00:00
- Shares Outstanding $863,788
Company brief: TREVENA, INC. (TRVN )
- Healthcare
- Biotechnology
- Ms. Carrie L. Bourdow
- https://www.trevena.com
- US
- N/A
- 01-31-2014
- US89532E2081
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.